#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Follicular lymphoma stage II Stress cardiomyopathy Giant cell tumour of tendon sheath Neuroblastoma recurrent Type IIa hyperlipidaemia Rheumatoid arthritis Eosinophilic oesophagitis Marfan's syndrome Hypergammaglobulinaemia benign monoclonal Multifocal motor neuropathy Dupuytren's contracture Selective polysaccharide antibody deficiency Dermatomyositis Waldenstrom's macroglobulinaemia refractory Neurodevelopmental disorder More trials…

    Learn about Rare Diseases

    Sarcoma – Life with Disease Acute respiratory distress syndrome – Life with Disease Systemic sclerosis pulmonary Biotinidase deficiency – Life with Disease Nephroblastoma – Diagnostics Hereditary hypophosphataemic rickets – Trials in Disease Hereditary ataxia – Life with Disease Ornithine transcarbamoylase deficiency – Life with Disease Leiomyosarcoma recurrent – Treatment Alagille syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Cerebrolysin Concentrate Lurbinectedin Bbp-398 Danazol Bms-986288 Gsk4527226 Codeine Phosphate Zolbetuximab Gandotinib Technetium (99Mtc) Posdinemab GSKVX000000048110 Migalastat Tafasitamab Fluoxetine Hydrochloride ABY-271 Memantine Hydrochloride Ruxotemitide Cd19-Car_Lenti_Allo Pelareorep More therapies…

    Learn about Your Condition

    Asthmatic crisis Inborn error of metabolism Lymphocytic leukaemia Ulcerative keratitis Acute HIV infection Chondroplasty Solitary fibrous tumour Osteogenesis imperfecta Skin neoplasm excision Behcet's syndrome Colitis ulcerative Biliary cancer metastatic Pulmonary embolism Non-obstructive cardiomyopathy Liver transplant rejection More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Axon Clinical s.r.o.

Axon Clinical s.r.o.

Ostrovskeho 253/3, Smichov, Prague, 150 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Efficacy and safety of ABP 938 compared with aflibercept in participants with neovascular age‑related macular degeneration

    Recruiting

    3 1 1
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Latvia Lithuania Poland Slovakia +1

  • A study to compare the efficacy and safety of AVT29 and aflibercept in patients with diabetic macular edema

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Aflibercept
    Bulgaria Czechia Hungary Latvia Poland Slovakia

  • A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Duvakitug
    Austria Belgium Bulgaria Czechia France Germany +9

  • Study of Surabgene Lomparvovec Compared to Ranibizumab for Adults with Wet Age-Related Macular Degeneration

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Ranibizumab
    Austria Belgium Bulgaria Croatia Czechia France +7

  • Testing icotrokinra compared to placebo for adults and adolescents with moderately to severely active ulcerative colitis

    Recruiting

    3 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • Study of icotrokinra for adults with moderately to severely active Crohn’s disease

    Recruiting

    4 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • ICOTROKINRA
    Belgium Czechia France Germany Greece Hungary +7

  • Study of incobotulinumtoxinA injections for prevention of chronic migraine in adult patients

    Recruiting

    3 1 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    Austria Czechia Denmark France Germany Italy +3

  • Study of ONL1204 eye injections to slow vision loss in patients with age-related macular degeneration and geographic atrophy

    Recruiting

    2 1
    Investigated Drugs:
    • XELAFASLATIDE
    Austria Czechia Germany Greece Hungary Italy +3

  • Study of oral BI 1815368 compared to placebo in patients with diabetic macular edema over 48 weeks of treatment

    Recruiting

    2 1
    Czechia Germany Hungary Poland Slovakia

  • Study on Long-term Safety of Zasocitinib for Adults with Moderate to Severe Ulcerative Colitis and Crohn’s Disease

    Recruiting

    2 1 1
    Investigated Diseases:
    • Colitis ulcerative
    • Crohn’s disease
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Czechia Denmark France Germany +8
1 2 3 … 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!